38.86 
0.02(0.05%) 4:00PM EDT|After Hours
:
38.86 0.00 (0.00%) 5:34PM EDT
| Prev Close: | 38.84 |
|---|
| Open: | 38.69 |
|---|
| Bid: | N/A |
|---|
| Ask: | 42.00 x 100 |
|---|
| 1y Target Est: | 40.06 |
|---|
| Beta: | 0.55 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 38.33 - 39.13 |
|---|
| 52wk Range: | 28.12 - 40.31 |
|---|
| Volume: | 322,691 |
|---|
| Avg Vol (3m): | 439,125 |
|---|
| Market Cap: | 2.62B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.33 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- First Week of November 16th Options Trading For Cepheid (CPHD)at Forbes(Wed 11:00AM EDT)
- Top Analyst Downgrades and Stocks to Sell: Cepheid, J.C. Penney, Walmart and More24/7 Wall St.(Tue, Oct 1)
- Insider Trading Alert - Cimarex Energy Company And 4 Others Traded By Insidersat TheStreet(Fri, Sep 27)
- A Growth Story in Molecular Diagnosticsat Motley Fool(Tue, Sep 10)
- First Week of March 2014 Options Trading For Cepheidat Forbes(Thu, Sep 5)
- Cepheid's TB Test OK'd by FDAZacks(Thu, Aug 29)
- Cepheid's Xpert MTB/RIF test categorized 'Moderate Complexity' by FDAat theflyonthewall.com(Wed, Aug 28)
- Cepheid Announces Xpert MTB/RIF Categorized 'Moderate Complexity' by FDAPR Newswire(Wed, Aug 28)
- Cepheid Breaks Below 200-Day Moving Average - Notable for CPHDat Forbes(Tue, Aug 27)
- Cardinal Health (CAH) Re-Establishing Medical Side of Business, With Positive Bias Toward Dividends: Expert Analyst Ross Muken Shares His Top Picks in Health Care with The Wall Street TranscriptWall Street Transcript(Tue, Aug 20)
- CEPHEID FinancialsEDGAR Online Financials(Thu, Aug 15)
- Cepheid Launches Mobile Community for 'Ride Against TB' Campaign to Benefit the American Lung AssociationPR Newswire(Thu, Aug 15)
- CEPHEID Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, Aug 7)
- Cepheid to Webcast Upcoming Financial PresentationsPR Newswire(Mon, Aug 5)
- Becton Dickinson Already Priced For Excellenceat Investopedia(Thu, Aug 1)
Key Statistics
| Forward P/E (1 yr): | 485.75 |
|---|
| P/S (ttm): | 7.26 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.26 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.11 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | -9.96 |
|---|
Business Summary
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market.
View More